The role of heterogeneous environment and docetaxel gradient in the emergence of polyploid, mesenchymal and resistant prostate cancer cells

Ke Chih Lin, Gonzalo Torga, Yusha Sun, Robert Axelrod, Kenneth J. Pienta, James Christopher Sturm, Robert Hamilton Austin

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The ability of a population of PC3 prostate epithelial cancer cells to become resistant to docetaxel therapy and progress to a mesenchymal state remains a fundamental problem. The progression towards resistance is difficult to directly study in heterogeneous ecological environments such as tumors. In this work, we use a micro-fabricated “evolution accelerator” environment to create a complex heterogeneous yet controllable in-vitro environment with a spatially-varying drug concentration. With such a structure we observe the rapid emergence of a surprisingly large number of polyploid giant cancer cells (PGCCs) in regions of very high drug concentration, which does not occur in conventional cell culture of uniform concentration. This emergence of PGCCs in a high drug environment is due to migration of diploid epithelial cells from regions of low drug concentration, where they proliferate, to regions of high drug concentration, where they rapidly convert to PGCCs. Such a mechanism can only occur in spatially-varying rather than homogeneous environments. Further, PGCCs exhibit increased expression of the mesenchymal marker ZEB1 in the same high-drug regions where they are formed, suggesting the possible induction of an epithelial to mesenchymal transition (EMT) in these cells. This is consistent with prior work suggesting the PGCC cells are mediators of resistance in response to chemotherapeutic stress. Taken together, this work shows the key role of spatial heterogeneity and the migration of proliferative diploid cells to form PGCCs as a survival strategy for the cancer population, with implications for new therapies.

Original languageEnglish (US)
Pages (from-to)97-108
Number of pages12
JournalClinical and Experimental Metastasis
Volume36
Issue number2
DOIs
StatePublished - Apr 15 2019

Fingerprint

docetaxel
Polyploidy
Prostatic Neoplasms
Giant Cells
Neoplasms
Pharmaceutical Preparations
Diploidy
Epithelial Cells
Epithelial-Mesenchymal Transition
Population

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Keywords

  • Cancer-on-a-chip
  • Cell migration
  • Chemotherapy gradient
  • Metastasis
  • Polyploid giant cancer cells
  • Tumor microenvironment

Cite this

@article{93df2c34b4794b61b2fd986c5b075928,
title = "The role of heterogeneous environment and docetaxel gradient in the emergence of polyploid, mesenchymal and resistant prostate cancer cells",
abstract = "The ability of a population of PC3 prostate epithelial cancer cells to become resistant to docetaxel therapy and progress to a mesenchymal state remains a fundamental problem. The progression towards resistance is difficult to directly study in heterogeneous ecological environments such as tumors. In this work, we use a micro-fabricated “evolution accelerator” environment to create a complex heterogeneous yet controllable in-vitro environment with a spatially-varying drug concentration. With such a structure we observe the rapid emergence of a surprisingly large number of polyploid giant cancer cells (PGCCs) in regions of very high drug concentration, which does not occur in conventional cell culture of uniform concentration. This emergence of PGCCs in a high drug environment is due to migration of diploid epithelial cells from regions of low drug concentration, where they proliferate, to regions of high drug concentration, where they rapidly convert to PGCCs. Such a mechanism can only occur in spatially-varying rather than homogeneous environments. Further, PGCCs exhibit increased expression of the mesenchymal marker ZEB1 in the same high-drug regions where they are formed, suggesting the possible induction of an epithelial to mesenchymal transition (EMT) in these cells. This is consistent with prior work suggesting the PGCC cells are mediators of resistance in response to chemotherapeutic stress. Taken together, this work shows the key role of spatial heterogeneity and the migration of proliferative diploid cells to form PGCCs as a survival strategy for the cancer population, with implications for new therapies.",
keywords = "Cancer-on-a-chip, Cell migration, Chemotherapy gradient, Metastasis, Polyploid giant cancer cells, Tumor microenvironment",
author = "Lin, {Ke Chih} and Gonzalo Torga and Yusha Sun and Robert Axelrod and Pienta, {Kenneth J.} and Sturm, {James Christopher} and Austin, {Robert Hamilton}",
year = "2019",
month = "4",
day = "15",
doi = "10.1007/s10585-019-09958-1",
language = "English (US)",
volume = "36",
pages = "97--108",
journal = "Clinical and Experimental Metastasis",
issn = "0262-0898",
publisher = "Springer Netherlands",
number = "2",

}

The role of heterogeneous environment and docetaxel gradient in the emergence of polyploid, mesenchymal and resistant prostate cancer cells. / Lin, Ke Chih; Torga, Gonzalo; Sun, Yusha; Axelrod, Robert; Pienta, Kenneth J.; Sturm, James Christopher; Austin, Robert Hamilton.

In: Clinical and Experimental Metastasis, Vol. 36, No. 2, 15.04.2019, p. 97-108.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The role of heterogeneous environment and docetaxel gradient in the emergence of polyploid, mesenchymal and resistant prostate cancer cells

AU - Lin, Ke Chih

AU - Torga, Gonzalo

AU - Sun, Yusha

AU - Axelrod, Robert

AU - Pienta, Kenneth J.

AU - Sturm, James Christopher

AU - Austin, Robert Hamilton

PY - 2019/4/15

Y1 - 2019/4/15

N2 - The ability of a population of PC3 prostate epithelial cancer cells to become resistant to docetaxel therapy and progress to a mesenchymal state remains a fundamental problem. The progression towards resistance is difficult to directly study in heterogeneous ecological environments such as tumors. In this work, we use a micro-fabricated “evolution accelerator” environment to create a complex heterogeneous yet controllable in-vitro environment with a spatially-varying drug concentration. With such a structure we observe the rapid emergence of a surprisingly large number of polyploid giant cancer cells (PGCCs) in regions of very high drug concentration, which does not occur in conventional cell culture of uniform concentration. This emergence of PGCCs in a high drug environment is due to migration of diploid epithelial cells from regions of low drug concentration, where they proliferate, to regions of high drug concentration, where they rapidly convert to PGCCs. Such a mechanism can only occur in spatially-varying rather than homogeneous environments. Further, PGCCs exhibit increased expression of the mesenchymal marker ZEB1 in the same high-drug regions where they are formed, suggesting the possible induction of an epithelial to mesenchymal transition (EMT) in these cells. This is consistent with prior work suggesting the PGCC cells are mediators of resistance in response to chemotherapeutic stress. Taken together, this work shows the key role of spatial heterogeneity and the migration of proliferative diploid cells to form PGCCs as a survival strategy for the cancer population, with implications for new therapies.

AB - The ability of a population of PC3 prostate epithelial cancer cells to become resistant to docetaxel therapy and progress to a mesenchymal state remains a fundamental problem. The progression towards resistance is difficult to directly study in heterogeneous ecological environments such as tumors. In this work, we use a micro-fabricated “evolution accelerator” environment to create a complex heterogeneous yet controllable in-vitro environment with a spatially-varying drug concentration. With such a structure we observe the rapid emergence of a surprisingly large number of polyploid giant cancer cells (PGCCs) in regions of very high drug concentration, which does not occur in conventional cell culture of uniform concentration. This emergence of PGCCs in a high drug environment is due to migration of diploid epithelial cells from regions of low drug concentration, where they proliferate, to regions of high drug concentration, where they rapidly convert to PGCCs. Such a mechanism can only occur in spatially-varying rather than homogeneous environments. Further, PGCCs exhibit increased expression of the mesenchymal marker ZEB1 in the same high-drug regions where they are formed, suggesting the possible induction of an epithelial to mesenchymal transition (EMT) in these cells. This is consistent with prior work suggesting the PGCC cells are mediators of resistance in response to chemotherapeutic stress. Taken together, this work shows the key role of spatial heterogeneity and the migration of proliferative diploid cells to form PGCCs as a survival strategy for the cancer population, with implications for new therapies.

KW - Cancer-on-a-chip

KW - Cell migration

KW - Chemotherapy gradient

KW - Metastasis

KW - Polyploid giant cancer cells

KW - Tumor microenvironment

UR - http://www.scopus.com/inward/record.url?scp=85062482198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062482198&partnerID=8YFLogxK

U2 - 10.1007/s10585-019-09958-1

DO - 10.1007/s10585-019-09958-1

M3 - Article

VL - 36

SP - 97

EP - 108

JO - Clinical and Experimental Metastasis

JF - Clinical and Experimental Metastasis

SN - 0262-0898

IS - 2

ER -